KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) Non Operating Investment Income (2016 - 2017)

Supernus Pharmaceuticals has reported Non Operating Investment Income over the past 6 years, most recently at $23000.0 for Q2 2017.

  • Quarterly Non Operating Investment Income fell 81.3% to $23000.0 in Q2 2017 from the year-ago period, while the trailing twelve-month figure was $77000.0 through Dec 2017, down 82.81% year-over-year, with the annual reading at $76000.0 for FY2017, 83.04% down from the prior year.
  • Non Operating Investment Income was $23000.0 for Q2 2017 at Supernus Pharmaceuticals, down from $54000.0 in the prior quarter.
  • Over five years, Non Operating Investment Income peaked at $760000.0 in Q3 2014 and troughed at -$8.6 million in Q2 2013.
  • The 5-year median for Non Operating Investment Income is $100000.0 (2016), against an average of -$545944.4.
  • Year-over-year, Non Operating Investment Income tumbled 5885.42% in 2013 and then surged 12200.0% in 2016.
  • A 5-year view of Non Operating Investment Income shows it stood at -$662000.0 in 2013, then soared by 204.83% to $694000.0 in 2014, then crashed by 81.7% to $127000.0 in 2015, then decreased by 22.05% to $99000.0 in 2016, then tumbled by 76.77% to $23000.0 in 2017.
  • Per Business Quant, the three most recent readings for SUPN's Non Operating Investment Income are $23000.0 (Q2 2017), $54000.0 (Q1 2017), and $99000.0 (Q4 2016).